Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New high affinity H3 receptor agonists without a basic side chain.

Ruengwit Kitbunnadaj1, Marcel Hoffmann, Silvina A Fratantoni

  • 1Leiden/Amsterdam Center of Drug Research (LACDR), Division of Medicinal Chemistry, Department of Pharmacochemistry, Faculty of Chemistry, Vrije Universiteit Amsterdam, The Netherlands.

Bioorganic & Medicinal Chemistry
|October 11, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis of 1,3-Disubstituted 3-Azabicyclo[3.2.0]heptane Libraries for Fragment-Based Drug Discovery.

Organic letters·2026
Same author

Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human Trial.

Ophthalmology science·2026
Same author

Pharmacological Characterization of a Novel Complement C3 Inhibitor Antibody Fragment.

Ophthalmology and therapy·2026
Same author

15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial.

Nature medicine·2026
Same author

Transcriptomic Analysis of Organotypic Porcine Retina Cultures.

International journal of molecular sciences·2026
Same author

Leveraging fragment-based drug discovery to advance 3D scaffolds into potent ligands: application to the histamine H<sub>1</sub> receptor.

RSC medicinal chemistry·2026

Researchers modified histamine H(3) receptor agonists by replacing amine groups with alcohol or hydrocarbon parts. The new compounds showed potent agonist activity and high selectivity for the H(3) receptor, with VUF5657 being the most effective.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Neuroscience

Background:

  • Histamine H(3) receptor agonists are crucial drug targets.
  • Previous agonists like imbutamine and immepip possess a basic amine function.
  • Exploring non-basic moieties could lead to novel receptor modulators.

Purpose of the Study:

  • To synthesize and evaluate novel histamine H(3) receptor agonists.
  • To investigate the impact of replacing the basic amine with alcohol or hydrocarbon groups.
  • To assess receptor affinity, functional activity, and selectivity over H(4) receptors.

Main Methods:

  • Chemical synthesis of novel compounds replacing amine with alcohol/hydrocarbon moieties.
  • In vitro assays to determine binding affinity (pK(i)) and functional activity (pEC(50)) for human H(3) and H(4) receptors.

Related Experiment Videos

  • Comparative analysis of novel compounds against parent alkylamine congeners.

    • Main Results:

    • All synthesized compounds exhibited moderate to high affinity for the human H(3) receptor.
    • Most compounds unexpectedly acted as potent agonists.
    • The alcohol series showed increased selectivity for H(3) over H(4) receptors.
    • VUF5657, a novel alcohol derivative, demonstrated the highest potency (pK(i) = 8.0, pEC(50) = 8.1) and 320-fold selectivity for H(3) over H(4).

    Conclusions:

    • Replacing the basic amine function with non-basic moieties can yield potent H(3) receptor agonists.
    • VUF5657 represents a highly selective and potent H(3) receptor agonist.
    • These findings offer new avenues for developing H(3) receptor-targeting therapeutics.